Pharmetheus https://validator.w3.org/feed/docs/rss2.html Pharmetheus at PAGE 2026 Events Pharmetheus at the 1st International PBPK Conference PAGE 2026 workshop: Mastering covariate modeling – hands-on with the Full Random Effects Model (FREM) approach Pharmetheus Board appoints Jonas Möller as new CEO Peter Milligan Leadership & Board of Directors PAGE 2026 workshop: PBPK & PBBM – linking biopharmaceutics to clinical performance with OSP suite  Jonas Möller Model-integrated evidence: A vision to expand the role of modeling in drug development and regulatory decision-making Large Language Model-Supported Data Collation: Addressing Accuracy and Reproducibility PBPK modeling of subcutaneous absorption for monoclonal antibodies Food effect prediction of a high permeability/low solubility drug formulated as an amorphous solid dispersion (ASD) using an Open Systems Pharmacology (OSP) PBBM approach A practical checklist for navigating CRO partnerships Rock and roll – deliverables driven by standardized data specifications News Home Open-source PBPK modeling of artemether for pediatric extrapolations: integrating enzyme ontogeny, CYP2B6 auto-induction and malnutrition An item response theory model with bounded integer subcomponents to describe the Mayo Clinic subscores in patients with ulcerative colitis A circular PK/PD/PK model explains the exposure of bulevirtide and bile salts in adult patients with Hepatitis D Usage and regulatory acceptance of PBPK models in paediatric drug applications: a review of EMA and FDA public assessment reports An open-source PBBM integrating the particle drifting effect to predict human oral absorption of nanoparticle formulations PBPK workflow for predicting clinical DDI risk of OATP1B1/3 inhibitors utilizing the CP-I biomarker: A case study with cyclosporine A Benchmarking a mechanistic immunogenicity framework: aligning sequence-based epitope predictions with clinical observations Model-informed fixed dosing of rozanolixizumab in gMG: PK/PD advantages and comparison with other FcRn blockers Visual predictive checks for real-world data using propensity-score-matching Training workshops Workshop catalog Crovalimab dose justification based on Phase 3 data in paroxysomal nocturnal hemoglobinurea patients The use of full random effect models (FREM) in model informed precision dosing (MIPD) for a priori dose predictions A mechanism-based parsimonious CAR-T cell population PK model and its validation via extension to a population PK-tumor size dynamics model: case study with axicabtagene ciloleucel and brexucabtagene autoleucel Apparent time dependence and rethinking random effect under single time-to-event models Martina Lundgren Food effect prediction of high permeability/low solubility, formulated as an amorphous solid dispersion (ASD) using an open systems pharmacology (OSP) PBBM approach Open Systems Pharmacology Community Conference (OSP-CC) Proceedings 2025 Population pharmacokinetic analysis of doxecitine and doxribtimine in patients with thymidine kinase 2 deficiency and in healthy volunteers Pharmetheus at GMP 2026 Symposium Pharmetheus at ESMO 2026 Pharmetheus at OSP Community Conference Workshop at ACoP 2026: Best use of TTE and RTTE modeling in NONMEM Quantitative Relationship Between Tominersen Concentrations in Cerebrospinal Fluid and Biomarker Changes in Huntington’s Disease Patients Model-Informed Drug Development in Small Populations Integrating in silico epitope prediction and mechanistic QSP modeling for benchmarking immunogenicity risk Population pharmacokinetics and exposure-response analyses of navepegritide in children with achondroplasia The decision-equivalence metric (DEM) method based evaluation of biomarker surrogacy in MASH The visual predictive check and real-world data Concentration-QTc (C-QTc) modeling Model-based approach for a new Prolonged-Release (PR) formulation of ivabradine: PK and PKPD assessment to support bioequivalence Predicting atorvastatin acid pharmacokinetics in a complex enzyme- and transporter-mediated drug–drug interaction network using physiologically based pharmacokinetic modeling Dose Modifications in Exposure-Response Analyses of Oncology Drug Development: Brigimadlin Case Study